Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 25 | 2023 | 97 | 6.200 |
Why?
|
| Prostate | 13 | 2022 | 32 | 3.460 |
Why?
|
| Kidney Neoplasms | 9 | 2023 | 70 | 2.400 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2023 | 43 | 1.770 |
Why?
|
| Image-Guided Biopsy | 11 | 2022 | 37 | 1.690 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 1084 | 1.440 |
Why?
|
| Robotic Surgical Procedures | 4 | 2023 | 34 | 1.160 |
Why?
|
| Robotics | 3 | 2023 | 25 | 1.070 |
Why?
|
| Nomograms | 1 | 2021 | 6 | 0.770 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 15 | 0.760 |
Why?
|
| Male | 39 | 2023 | 13917 | 0.710 |
Why?
|
| Humans | 48 | 2023 | 25692 | 0.630 |
Why?
|
| Nephrectomy | 5 | 2017 | 35 | 0.630 |
Why?
|
| Waiting Lists | 1 | 2017 | 16 | 0.580 |
Why?
|
| Kidney Transplantation | 3 | 2017 | 120 | 0.580 |
Why?
|
| Renal Dialysis | 1 | 2017 | 115 | 0.540 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 4 | 0.530 |
Why?
|
| Retrospective Studies | 12 | 2023 | 3220 | 0.520 |
Why?
|
| Ultrasonography, Interventional | 6 | 2020 | 68 | 0.510 |
Why?
|
| Heterozygote | 1 | 2016 | 91 | 0.510 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 15 | 0.500 |
Why?
|
| Ultrasonography | 6 | 2019 | 235 | 0.460 |
Why?
|
| Biopsy | 6 | 2022 | 199 | 0.460 |
Why?
|
| Middle Aged | 26 | 2022 | 8403 | 0.440 |
Why?
|
| Aged | 18 | 2022 | 8501 | 0.410 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 9 | 0.400 |
Why?
|
| Perineum | 2 | 2021 | 6 | 0.390 |
Why?
|
| Laparoscopy | 3 | 2023 | 170 | 0.390 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2017 | 30 | 0.360 |
Why?
|
| Kidney Diseases | 2 | 2012 | 98 | 0.350 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2021 | 8 | 0.340 |
Why?
|
| Prostatic Hyperplasia | 3 | 2013 | 8 | 0.320 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 25 | 0.270 |
Why?
|
| Prospective Studies | 6 | 2023 | 1633 | 0.270 |
Why?
|
| Kidney | 3 | 2023 | 155 | 0.270 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 30 | 0.260 |
Why?
|
| Adult | 14 | 2017 | 7336 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4459 | 0.230 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 19 | 0.220 |
Why?
|
| Ureter | 1 | 2023 | 26 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 281 | 0.220 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2022 | 2 | 0.200 |
Why?
|
| Cystectomy | 2 | 2019 | 9 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 26 | 0.190 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 5 | 0.190 |
Why?
|
| Prostatectomy | 2 | 2023 | 20 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2004 | 11 | 0.170 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 443 | 0.170 |
Why?
|
| Urinary Bladder | 1 | 2019 | 22 | 0.170 |
Why?
|
| Urology | 1 | 2019 | 14 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 35 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 333 | 0.160 |
Why?
|
| Survival Rate | 2 | 2017 | 308 | 0.160 |
Why?
|
| Ablation Techniques | 1 | 2017 | 2 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2017 | 20 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 53 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 34 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 3 | 0.140 |
Why?
|
| Phototherapy | 1 | 2017 | 32 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2017 | 52 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 19 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2017 | 53 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 39 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 170 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 6 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 3 | 2004 | 7 | 0.130 |
Why?
|
| Disease Management | 2 | 2016 | 97 | 0.120 |
Why?
|
| Succinate Dehydrogenase | 1 | 2015 | 2 | 0.120 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2015 | 2 | 0.120 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 7 | 0.120 |
Why?
|
| Animals | 5 | 2017 | 3510 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 40 | 0.120 |
Why?
|
| Female | 10 | 2017 | 14273 | 0.120 |
Why?
|
| Kallikreins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Prognosis | 5 | 2017 | 739 | 0.120 |
Why?
|
| United States | 2 | 2017 | 1943 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2013 | 3 | 0.110 |
Why?
|
| Time Factors | 1 | 2017 | 1336 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 56 | 0.110 |
Why?
|
| Urothelium | 1 | 2013 | 5 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 5 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 25 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 12 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 66 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 299 | 0.100 |
Why?
|
| Fungal Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Threonine | 1 | 2011 | 10 | 0.090 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 7 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1689 | 0.090 |
Why?
|
| SEER Program | 3 | 2015 | 37 | 0.090 |
Why?
|
| Nitriles | 2 | 2022 | 13 | 0.080 |
Why?
|
| Young Adult | 4 | 2015 | 1855 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 221 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2023 | 3231 | 0.070 |
Why?
|
| Adolescent | 4 | 2015 | 2076 | 0.070 |
Why?
|
| Malacoplakia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pyelonephritis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Tuberculosis, Renal | 1 | 2006 | 1 | 0.070 |
Why?
|
| Emphysema | 1 | 2006 | 4 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 2224 | 0.070 |
Why?
|
| Abscess | 1 | 2006 | 28 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 341 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 6 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 8 | 0.060 |
Why?
|
| Child | 3 | 2015 | 1277 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 13 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2016 | 246 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 118 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 1 | 2023 | 10 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2023 | 14 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 8 | 0.050 |
Why?
|
| Organ Size | 2 | 2013 | 103 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 169 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Watchful Waiting | 1 | 2022 | 10 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 14 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 48 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 76 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 96 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 24 | 0.050 |
Why?
|
| Patient Selection | 2 | 2013 | 170 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 22 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 16 | 0.050 |
Why?
|
| HIV Infections | 1 | 2006 | 457 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 103 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 3 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 8 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 7 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 1345 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 315 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 472 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 646 | 0.040 |
Why?
|
| Education | 1 | 2019 | 42 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 35 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 1781 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2017 | 1 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 3 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 6 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2002 | 827 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 185 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2015 | 2 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 24 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 84 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 75 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 255 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 2 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2014 | 45 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 618 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 68 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 7 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 329 | 0.030 |
Why?
|
| Dutasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Azasteroids | 1 | 2013 | 2 | 0.030 |
Why?
|
| Finasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 48 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 26 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 95 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 2 | 0.030 |
Why?
|
| Propionates | 1 | 2013 | 11 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 17 | 0.030 |
Why?
|
| Michigan | 1 | 2013 | 14 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 18 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 67 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 217 | 0.030 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 81 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 152 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 292 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 167 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 90 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 24 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 351 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 198 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 75 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 664 | 0.020 |
Why?
|
| Solvents | 1 | 2011 | 4 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 49 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 89 | 0.020 |
Why?
|
| Chaperonins | 1 | 2011 | 1 | 0.020 |
Why?
|
| Casein Kinase II | 1 | 2011 | 2 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 18 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 731 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 12 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 17 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 56 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 410 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 134 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 584 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 716 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 869 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 847 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 2 | 0.010 |
Why?
|
| Thymidine | 1 | 2004 | 6 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 5 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 18 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 79 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 39 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 107 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 96 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 177 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 13 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2003 | 5 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 66 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 150 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 284 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 4 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 37 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 248 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 29 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 40 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 46 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 649 | 0.010 |
Why?
|